LifeScience Alley, which represents the medical device industry in Minnesota, announced Wednesday that former Medtronic CEO Bill Hawkins will be the inaugural chairman of a new public-private partnership to advance regulatory science. Regulatory science is a set of tools and methods for evaluating the safety, effectiveness, quality and performance of medical devices. The three entities […]
They gave him a sword and he handed them the world. When William Hawkins officially flipped the keys to Medtronic Inc. (NYSE:MDT) over to successor Omar Ishrak, he offered a simple message and a gift. The message was clear – don’t lose sight of founder Earl Bakken’s mission to alleviate pain, restore health and extend […]
Williams Hawkins, the former CEO of Medtronic Inc. (NYSE:MDT), pulled down $5.5 million in salary and benefits during fiscal 2011, according to a regulatory filing. Hawkins stands to do pretty well this year too, as his severance package includes a deal to stay on for fiscal 2012 at the same pay rate, according to the […]
Medtronic Inc. has lured away the President and CEO of GE Healthcare Systems Omar Ishrak to replace current Chairman and CEO Bill Hawkins, who is retiring. Come June 13, Ishrak will take over running the world’s largest medical device company, based in Fridley, Minnesota. GE Healthcare Systems is a $12 billion division of GE Healthcare […]
What to make of Medtronic (NYSE:MDT) CEO Bill Hawkins’ decision to postpone his retirement? A spokesman for the Fridley, Minnesota-based company declined to answer any questions about the search for a new CEO. But one thing is clear: something transpired between Feb. 22, when Hawkins told analysts it would be the last time he would […]
Medtronic Chairman and CEO Bill Hawkins sent a note to employees Monday saying that he will stay on longer than he initially intended because the search for his successor is taking longer than expected. Hawkins was expected to retire at the end of fiscal year 2011, which ended in late April. But on Monday, he […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Medtronic Inc. (NYSE: MDT) says it's resolved U.S. Food and Drug Administration warning letter issues at two manufacturing facilities -- clearing the way for new product launches.
Medtronic is on the hunt for a new CEO to replace Bill Hawkins. Could a current board member be the chosen one?
Medtronic Inc. (NYSE:MDT) will fund a clinical trial for Nile Therapeutics Inc. (NSDQ:NLTX) behind a peptide treatment for heart failure. The San Mateo, Calif. biopharmaceutical company said Medtronic will also provide expertise on building a drug-device combination as Nile completes a Phase I trial to "assess the pharmacokinetics and phamacodynamics of cenderitide delivered through Medtronic diabetes pump technology," according to a prepared release.
How quickly new innovative medical devices get to market will be determined in part by changes in the U.S. Food and Drug Administration's 510(k) program. Outgoing Medtronic (NYSE:MDT) Chief Executive Bill Hawkins said this week that updates to 510(k) "will be neutral to slightly negative."
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Hawkins won't be required to report to work, but instead make himself available to advise on everything from litigation and community affairs to talent retention and industry leadership, according to the separation letter, dated Dec. 28. He will receive on top of his current annual salary of $1.25 million an expected $3.8 million in separation pay.
Medtronic (NYSE:MDT) announced this week that CEO Bill Hawkins will retire in April 2011 after just three-plus years on the job. While his tenure was relatively short, Hawkins left an indelible mark on the world's largest maker of new innovative medical devices. Here's a look back on the Hawkins era at Medtronic.
It's been that kind of day at Medtronic Inc. (NYSE:MDT). In the morning, the company in Fridley, Minnesota, announced current CEO Bill Hawkins would retire next year. In the afternoon, Medtronic announced one of its former CEOs, Winston Wallin, had died at the age of 84.
When Medtronic Inc. (NYSE:MDT) CEO Art Collins retired in 2007, there were at least two top candidates vying to replace him. One was Michael DeMane, the brash president of Medtronic's spine business whose aggressive pursuit of growth invited legal and regulatory scrutiny. The other was chief operating officer Bill Hawkins, a steady, stabilizing presence within Medtronic's senior leadership team.
Medtronic Inc. (NYSE:MDT) said Monday that Chairman/CEO Bill Hawkins will retire next year. The medical device giant based in Fridley, Minnesota, said Hawkins, 56, will leave the company April 2011. Medtronic will launch an external search for his replacement.
